
Sign up to save your podcasts
Or


(00:50)
So maybe we'll just start with a simple question. If you could tell us a little bit about you and your background?
(01:21)
Let's go into, then, the dendritic cell enumeration test. What is this exactly?
(03:46)
What's innovative or different about this test?
(04:56)
What would you say is the primary use case of this test?
(06:02)
So how would you foresee this test being used?
(08:06)
So do you think that we'll be using this test for perhaps our very sick individuals here at Mayo Clinic?
(08:37)
So how would someone order this test? Is it available outside of Mayo Clinic, as well?
(08:52)
Is there anything else that you'd like to share about this whole process and coming up with this really novel test?
Tell us a little bit about your background and about yourself.
Give us a brief overview of what are the previous approaches that have been used in the past for multiple myeloma testing.
So can you take a moment and talk to me about the new approach and the new algorithm that your laboratory is working on implementing?
So how does this new approach really benefit both hospitals across the country that we serve and the patients that they're trying to treat?
What else is the lab working on when it comes to our multiple myeloma testing and our algorithms?
Resources
Plasma Cell Proliferative Disorder [A Test in Focus]
Plasma Cell Proliferative Disorder, FISH, Bone Marrow (Mayo test ID: PCPDS)
Mayo Algorithmic Approach for Stratification of Myeloma and Risk-Adapted Therapy Report, Bone Marrow (Mayo test ID: MSMRT)
Chromosome Analysis, Hematologic Disorders, Bone Marrow (Mayo test ID: CHRBM)
Mellors et al.: Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. Blood Advances. 2020;4(10): 2236-2244
https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-research-confirms-critical-role-of-masks-in-preventing-covid-19-infection/
(00:48)
Could you provide our listeners with a little bit about you and your background?
(01:56)
There's a fair amount of genetic hearing loss tests out there. Why did we decide to develop this one here at Mayo?
(02:51)
Can you tell me a little bit about the process that actually went into developing the test — the different research and that sort of thing?
(04:03)
What specific need do we meet with this particular test?
(06:22)
How were these results used in patient care? And what I mean by that is, when you're talking about the downstream management of the patient, what are some of the different treatments that can result from the use of this test?
(08:16)
How does our test compare to some of these tests that are out there right now?
(09:48)
Where in the patient's journey would this test be used? I know it's a diagnostic test and not a screening test, but could you expand on that a little more for me?
From the publisher's feed

31,923 Listeners

3,164 Listeners

11,826 Listeners

10,631 Listeners

112,026 Listeners

56,533 Listeners

46,720 Listeners